Novel Therapeutics for Metastatic Renal Cell Carcinoma
Novel Therapeutics for Metastatic Renal Cell Carcinoma
复制标题
DOI：
10.1002/cncr.24235
复制
发表时间：
2009-05-15
期刊：
影响因子：
6.2
通讯作者：
Figlin, Robert A.
中科院分区：
文献类型：
--
作者：
Hutson, Thomas E.;Figlin, Robert A.
在过去的几年中，转移性肾细胞癌（RCC）的治疗发生了巨大的变化。苹果酸舒尼替尼、托磺酸索拉非尼、贝伐单抗联合干扰素α、替西莫司和依维莫司在随机3期试验中通过抑制血管内皮生长因子和相关途径改善了临床结果。正在评估这些药物的组合和顺序。其他新型药物正在临床开发中，其中一些靶向尚未被用于RCC治疗的新途径。最近报道和正在进行的临床试验将有助于进一步确定这些药物作为转移性肾细胞癌治疗的作用。癌症2009;115(10): 2361 - 7。(C) 2009年美国癌症协会。
The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically during the past few years. Sunitinib malate, sorafenib tosylate, bevacizumab with interferon alpha, temsirolimus, and everolimus have improved clinical outcomes in randomized phase 3 trials by inhibiting the vascular endothelial growth factor and related pathways. Combinations and sequences of these agents are being evaluated. Other novel agents are in clinical development, some of which target novel pathways not yet exploited as therapy for RCC. Recently reported and ongoing clinical trials will help further define the role of these agents as therapy for metastatic RCC. Cancer 2009;115(10 suppl):2361-7. (C) 2009 American Cancer Society.